Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.